Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C6H13NO5.2Cl.2K.H2O4S |
Molecular Weight | 605.523 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[K+].[K+].OS(O)(=O)=O.N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO.N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=ZGYRLIPOHALCCV-VQRMJQQYSA-L
InChI=1S/2C6H13NO5.2ClH.2K.H2O4S/c2*7-3(1-8)5(11)6(12)4(10)2-9;;;;;1-5(2,3)4/h2*1,3-6,9-12H,2,7H2;2*1H;;;(H2,1,2,3,4)/q;;;;2*+1;/p-2/t2*3-,4+,5+,6+;;;;;/m00...../s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | O4S |
Molecular Weight | 96.063 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H13NO5 |
Molecular Weight | 179.1711 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | K |
Molecular Weight | 39.0983 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/npp/glucosamine.html
Sources: https://www.drugs.com/npp/glucosamine.html
Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. Glucosamine is part of the structure of the polysaccharides chitosan and chitin, which compose the exoskeletons of crustaceans and other arthropods, as well as the cell walls of fungi and many higher organisms. Glucosamine is one of the most abundant monosaccharides. It is produced commercially by the hydrolysis of crustacean exoskeletons or, less commonly, by fermentation of a grain such as corn or wheat. Oral glucosamine is a dietary supplement and is not a pharmaceutical drug. It is illegal in the US to market any dietary supplement as a treatment for any disease or condition. Glucosamine is marketed to support the structure and function of joints, and the marketing is targeted to people suffering from osteoarthritis. Commonly sold forms of glucosamine are glucosamine sulfate, glucosamine hydrochloride, and N-acetylglucosamine. Of the three commonly available forms of glucosamine, only glucosamine sulfate is given a "likely effective" rating for treating osteoarthritis. Glucosamine is often sold in combination with other supplements such as chondroitin sulfate and methylsulfonylmethane. Glucosamine, along with commonly used chondroitin, is not routinely prescribed to treat people who have symptomatic osteoarthritis of the knee, as there is insufficient evidence that this treatment is helpful. One clinical study over three years showed that glucosamine in doses of 1500 mg per day is safe to use. Glucosamine with or without chondroitin elevates the international normalized ratio (INR) in individuals who are taking the blood thinner, warfarin. It may also interfere with the efficacy of chemotherapy for treating cancer symptoms. Adverse effects may include stomach upset, constipation, diarrhea, headache, and rash. There are case reports of people who have chronic liver disease and a worsening of their condition with glucosamine supplementation. Glucosamine is naturally present in the shells of shellfish, animal bones, bone marrow, and fungi. D-Glucosamine is made naturally in the form of glucosamine-6-phosphate, and is the biochemical precursor of all nitrogen-containing sugars. Specifically in humans, glucosamine-6-phosphate is synthesized from fructose 6-phosphate and glutamine by glutamine—fructose-6-phosphate transaminase as the first step of the hexosamine biosynthesis pathway. The end-product of this pathway is uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), which is then used for making glycosaminoglycans, proteoglycans, and glycolipids. As the formation of glucosamine-6-phosphate is the first step for the synthesis of these products, glucosamine may be important in regulating their production; however, the way that the hexosamine biosynthesis pathway is actually regulated, and whether this could be involved in contributing to human disease remains unclear.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23571415 |
|||
Target ID: CHEMBL1743121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23571415 |
|||
Target ID: CHEMBL5685 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18788725 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Glucosamine Approved UseUnknown |
|||
Primary | Glucosamine Approved UseUnknown |
|||
Primary | Oral Lichen Planus Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Experience with glucosamine hydrochloride in the treatment of patients with osteoarthrosis]. | 2005 |
|
Inhibitory effects of glucosamine on lipopolysaccharide-induced activation in microglial cells. | 2005 Dec |
|
Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. | 2006 |
|
Double blind investigation of the effects of oral supplementation of combined glucosamine hydrochloride (GHCL) and chondroitin sulphate (CS) on stride characteristics of veteran horses. | 2006 Aug |
|
Arthritic disease suppression and cartilage protection with glycosaminoglycan polypeptide complexes (Peptacans) derived from the cartilage extracellular matrix: a novel approach to therapy. | 2006 Aug |
|
Glucosamine sulfate inhibits proinflammatory cytokine-induced icam-1 production in human conjunctival cells in vitro. | 2006 Dec |
|
Enhanced chondrogenic differentiation of murine embryonic stem cells in hydrogels with glucosamine. | 2006 Dec |
|
Glucosamine sulfate inhibits TNF-alpha and IFN-gamma-induced production of ICAM-1 in human retinal pigment epithelial cells in vitro. | 2006 Feb |
|
Determination of the degree of acetylation of chitosan by UV spectrophotometry using dual standards. | 2006 May 1 |
|
An optimized reverse-phase high performance liquid chromatographic method for evaluating percutaneous absorption of glucosamine hydrochloride. | 2006 May 3 |
|
Glucosamine sulfate inhibits leukocyte adhesion in response to cytokine stimulation of retinal pigment epithelial cells in vitro. | 2006 Nov |
|
[The influence of experimental therapy on the dynamics of endogenous glucosamine content in laboratory animals with nephropathy]. | 2006 Nov-Dec |
|
Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis. | 2006 Oct |
|
Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL. | 2006 Oct |
|
An analysis of high glucose and glucosamine-induced gene expression and oxidative stress in renal mesangial cells. | 2006 Oct-Dec |
|
Glucosamine hydrochloride for the treatment of osteoarthritis symptoms. | 2007 |
|
Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. | 2007 |
|
Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. | 2007 |
|
Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation. | 2007 |
|
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. | 2007 |
|
Establishment of a novel corneal endothelial cell line from domestic rabbit, Oryctolagus curiculus. | 2007 Apr |
|
[A comparison study on the physical/chemical properties and immunomodulatory activities of mycelial polysaccharide extracts from five Ganoderma species]. | 2007 Aug |
|
Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt (GlcN.S) and covalent glucosamine sulfates (GlcN-SO4). | 2007 Aug |
|
Systematic review of clinical trials of treatments for osteoarthritis in dogs. | 2007 Feb 15 |
|
Factors affecting trypanosome maturation in tsetse flies. | 2007 Feb 21 |
|
Effects of glucosamine administration on patients with rheumatoid arthritis. | 2007 Jan |
|
Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. | 2007 Jul |
|
Glucosamine for pain in osteoarthritis: why do trial results differ? | 2007 Jul |
|
[Efficacy and safety evaluation of glucosamine hydrochloride in the treatment of osteoarthritis]. | 2007 Jul 15 |
|
Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells. | 2007 Jul 15 |
|
Collagen Synthesis in tenocytes, ligament cells and chondrocytes exposed to a combination of Glucosamine HCl and chondroitin sulfate. | 2007 Jun |
|
Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. | 2007 Jun |
|
Preparation of glucosamine from exoskeleton of shrimp and predicting production yield by response surface methodology. | 2007 Mar 21 |
|
The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. | 2007 May |
|
Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. | 2007 May |
|
[Effect of glucosamine sulfate on the analgesic and ulcerogenic activity of ketoprofen]. | 2007 May-Jun |
|
[Determination of glucosamine hydrochloride in complex formula by RP-HPLC coupled with evaporative light scattering detection]. | 2007 Nov |
|
The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. | 2007 Nov |
|
Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. | 2007 Nov |
|
Glucosamine and its N-acetyl-phenylalanine derivative prevent TNF-alpha-induced transcriptional activation in human chondrocytes. | 2007 Nov-Dec |
|
Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. | 2007 Oct |
|
Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. | 2007 Oct 31 |
|
Treatment of primary and secondary osteoarthritis of the knee. | 2007 Sep |
|
Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. | 2007 Sep 21 |
|
A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. | 2008 Feb 17 |
|
Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. | 2008 Jan |
|
Sulfated glucosamine inhibits oxidation of biomolecules in cells via a mechanism involving intracellular free radical scavenging. | 2008 Jan 28 |
|
Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-stimulated RAW264.7 cells by carboxybutyrylated glucosamine takes place via down-regulation of mitogen-activated protein kinase-mediated nuclear factor-kappaB signaling. | 2008 Mar |
|
Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. | 2008 May 1 |
|
Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. | 2008 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npp/glucosamine.html
In clinical studies of arthritis, glucosamine dosage has typically been 1.5 g/day, as a single dose or in divided doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10891367
To induce insulin resistance 3T3-L1 adipocytes were treated with DMEM containing 10% FBS and 2 mM glucosamine, and in the absence of glucose, glutamine, and insulin. Since glucosamine bypasses the GFAT step to enter the hexosamine pathway, glutamine is not needed for glucosamineinduced insulin resistance
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:53:09 GMT 2023
by
admin
on
Sat Dec 16 08:53:09 GMT 2023
|
Record UNII |
15VQ11I66N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1296149-08-0
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
76965765
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
15VQ11I66N
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
15VQ11I66N
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
SUB26636
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
100000091426
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110916
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
1789517
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY | |||
|
216699-44-4
Created by
admin on Sat Dec 16 08:53:09 GMT 2023 , Edited by admin on Sat Dec 16 08:53:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|